UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.
UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.